These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31437400)

  • 1. Reply to Bogaard
    Kojonazarov B; Hadzic S; Ghofrani HA; Grimminger F; Seeger W; Weissmann N; Schermuly RT
    Am J Respir Crit Care Med; 2019 Dec; 200(11):1450-1452. PubMed ID: 31437400
    [No Abstract]   [Full Text] [Related]  

  • 2. Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Bogaard HJ; Legchenko E; Chaudhary KR; Sun XQ; Stewart DJ; Hansmann G
    Am J Respir Crit Care Med; 2019 Dec; 200(11):1447-1450. PubMed ID: 31437404
    [No Abstract]   [Full Text] [Related]  

  • 3. The Adult Sprague-Dawley Sugen-Hypoxia Rat Is Still "the One:" A Model of Group 1 Pulmonary Hypertension: Reply to Le Cras and Abman.
    Bogaard HJ; Legchenko E; Ackermann M; Kühnel MP; Jonigk DD; Chaudhary KR; Sun X; Stewart DJ; Hansmann G
    Am J Respir Crit Care Med; 2020 Mar; 201(5):621-624. PubMed ID: 31769697
    [No Abstract]   [Full Text] [Related]  

  • 4. The Sugen 5416/Hypoxia Mouse Model of Pulmonary Arterial Hypertension.
    Bueno-Beti C; Hadri L; Hajjar RJ; Sassi Y
    Methods Mol Biol; 2018; 1816():243-252. PubMed ID: 29987825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2017 Sep; 810():83-91. PubMed ID: 28576407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension.
    Kojonazarov B; Hadzic S; Ghofrani HA; Grimminger F; Seeger W; Weissmann N; Schermuly RT
    Am J Respir Crit Care Med; 2019 Aug; 200(4):515-518. PubMed ID: 31034778
    [No Abstract]   [Full Text] [Related]  

  • 7. Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.
    Kato F; Sakao S; Takeuchi T; Suzuki T; Nishimura R; Yasuda T; Tanabe N; Tatsumi K
    Am J Physiol Lung Cell Mol Physiol; 2017 Nov; 313(5):L899-L915. PubMed ID: 28798259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Disruption of VEGF Receptor Signaling and the Risk for Adult Emphysema.
    Le Cras TD; Abman SH
    Am J Respir Crit Care Med; 2020 Mar; 201(5):620-621. PubMed ID: 31769719
    [No Abstract]   [Full Text] [Related]  

  • 9. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CrossTalk proposal: The mouse SuHx model is a good model of pulmonary arterial hypertension.
    Penumatsa KC; Warburton RR; Hill NS; Fanburg BL
    J Physiol; 2019 Feb; 597(4):975-977. PubMed ID: 30499212
    [No Abstract]   [Full Text] [Related]  

  • 11. CrossTalk opposing view: The mouse SuHx model is not a good model of pulmonary arterial hypertension.
    Vitali SH
    J Physiol; 2019 Feb; 597(4):979-981. PubMed ID: 30499185
    [No Abstract]   [Full Text] [Related]  

  • 12. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
    Oka M; Homma N; Taraseviciene-Stewart L; Morris KG; Kraskauskas D; Burns N; Voelkel NF; McMurtry IF
    Circ Res; 2007 Mar; 100(6):923-9. PubMed ID: 17332430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for hypoxic exposure in experimental PAH - Comment on Chen et al.: a novel rat model of pulmonary hypertension induced by mono treatment with SU5416.
    de Raaf MA; Schalij I; Bogaard HJ
    Hypertens Res; 2020 Nov; 43(11):1313-1314. PubMed ID: 32884125
    [No Abstract]   [Full Text] [Related]  

  • 14. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.
    Christou H; Hudalla H; Michael Z; Filatava EJ; Li J; Zhu M; Possomato-Vieira JS; Dias-Junior C; Kourembanas S; Khalil RA
    J Pharmacol Exp Ther; 2018 Feb; 364(2):258-274. PubMed ID: 29212831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen-hypoxia rat model by cardiac magnetic resonance imaging.
    Jayasekera G; Wilson KS; Buist H; Woodward R; Uckan A; Hughes C; Nilsen M; Church AC; Johnson MK; Gallagher L; Mullin J; MacLean MR; Holmes WM; Peacock AJ; Welsh DJ
    Pulm Circ; 2020; 10(1):2045894019897513. PubMed ID: 32095230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
    Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
    Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension.
    Poble PB; Phan C; Quatremare T; Bordenave J; Thuillet R; Cumont A; Huertas A; Tu L; Dorfmüller P; Humbert M; Ghigna MR; Savale L; Guignabert C
    FASEB J; 2019 Mar; 33(3):3670-3679. PubMed ID: 30481487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Aryl Hydrocarbon Receptor in Su5416/Hypoxia-induced Pulmonary Hypertension: A New Mechanism for an "Old" Model.
    Strielkov I; Weissmann N
    Am J Respir Cell Mol Biol; 2018 Mar; 58(3):279-281. PubMed ID: 29493322
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.
    McLendon JM; Joshi SR; Sparks J; Matar M; Fewell JG; Abe K; Oka M; McMurtry IF; Gerthoffer WT
    J Control Release; 2015 Jul; 210():67-75. PubMed ID: 25979327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.